148 related articles for article (PubMed ID: 23910175)
1. HER2 status in gastric cancer: a comparison of two novel in situ hybridization methods (IQ FISH and dual color SISH) and two immunohistochemistry methods (A0485 and HercepTest™).
Pala EE; Bayol U; Ozguzer A; Akman O
Pathol Res Pract; 2013 Sep; 209(9):548-54. PubMed ID: 23910175
[TBL] [Abstract][Full Text] [Related]
2. Validation and workflow optimization of human epidermal growth factor receptor 2 testing using INFORM HER2 dual-color in situ hybridization.
Lim SJ; Cantillep A; Carpenter PM
Hum Pathol; 2013 Nov; 44(11):2590-6. PubMed ID: 24075600
[TBL] [Abstract][Full Text] [Related]
3. Human epidermal growth factor receptor 2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and resections.
Lee S; de Boer WB; Fermoyle S; Platten M; Kumarasinghe MP
Histopathology; 2011 Nov; 59(5):832-40. PubMed ID: 22092394
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization: which scoring system should we use?
Park YS; Hwang HS; Park HJ; Ryu MH; Chang HM; Yook JH; Kim BS; Jang SJ; Kang YK
Hum Pathol; 2012 Mar; 43(3):413-22. PubMed ID: 21855114
[TBL] [Abstract][Full Text] [Related]
5. HER2-testing in 538 consecutive breast cancer cases using FISH and immunohistochemistry.
Kovács A; Stenman G
Pathol Res Pract; 2010 Jan; 206(1):39-42. PubMed ID: 19819642
[TBL] [Abstract][Full Text] [Related]
6. Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists.
Dietel M; Ellis IO; Höfler H; Kreipe H; Moch H; Dankof A; Kölble K; Kristiansen G
Virchows Arch; 2007 Jul; 451(1):19-25. PubMed ID: 17562074
[TBL] [Abstract][Full Text] [Related]
7. Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation assay enables accurate assessment of HER2 genomic status in gastric cancer and has potential utility in HER2 testing of biopsy samples.
Yan B; Yau EX; Choo SN; Ong CW; Yong KJ; Pang B; Salto-Tellez M
J Clin Pathol; 2011 Oct; 64(10):880-3. PubMed ID: 21757431
[TBL] [Abstract][Full Text] [Related]
8. Gastric HER2 Testing Study (GaTHER): an evaluation of gastric/gastroesophageal junction cancer testing accuracy in Australia.
Fox SB; Kumarasinghe MP; Armes JE; Bilous M; Cummings MC; Farshid G; Fitzpatrick N; Francis GD; McCloud PI; Raymond W; Morey A
Am J Surg Pathol; 2012 Apr; 36(4):577-82. PubMed ID: 22314190
[TBL] [Abstract][Full Text] [Related]
9. Comparison of four immunohistochemical tests and FISH for measuring HER2 expression in gastric carcinomas.
Cho EY; Srivastava A; Park K; Kim J; Lee MH; Do I; Lee J; Kim KM; Sohn TS; Kang WK; Kim S
Pathology; 2012 Apr; 44(3):216-20. PubMed ID: 22437741
[TBL] [Abstract][Full Text] [Related]
10. Bright-field in situ hybridization for HER2 gene amplification in breast cancer using tissue microarrays: correlation between chromogenic (CISH) and automated silver-enhanced (SISH) methods with patient outcome.
Francis GD; Jones MA; Beadle GF; Stein SR
Diagn Mol Pathol; 2009 Jun; 18(2):88-95. PubMed ID: 19430296
[TBL] [Abstract][Full Text] [Related]
11. [Dual-color silver-enhanced in-situ hybridization and fluorescence in-situ hybridization for determination of HER2 gene status in gastric carcinoma].
Long XY; Bu H; Wei B; Liu XY; Chen M; Chen J; Liu JP
Zhonghua Bing Li Xue Za Zhi; 2011 May; 40(5):300-3. PubMed ID: 21756822
[TBL] [Abstract][Full Text] [Related]
12. IHC for Her2 with CBE356 antibody is a more accurate predictor of Her2 gene amplification by FISH than HercepTest in breast carcinoma.
Ainsworth R; Bartlett JM; Going JJ; Mallon EA; Forsyth A; Richmond J; Angerson W; Watters A; Dunne B
J Clin Pathol; 2005 Oct; 58(10):1086-90. PubMed ID: 16189156
[TBL] [Abstract][Full Text] [Related]
13. Silver in situ hybridization (SISH) for determination of HER2 gene status in breast carcinoma: comparison with FISH and assessment of interobserver reproducibility.
Papouchado BG; Myles J; Lloyd RV; Stoler M; Oliveira AM; Downs-Kelly E; Morey A; Bilous M; Nagle R; Prescott N; Wang L; Dragovich L; McElhinny A; Garcia CF; Ranger-Moore J; Free H; Powell W; Loftus M; Pettay J; Gaire F; Roberts C; Dietel M; Roche P; Grogan T; Tubbs R
Am J Surg Pathol; 2010 Jun; 34(6):767-76. PubMed ID: 20421783
[TBL] [Abstract][Full Text] [Related]
14. Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer.
Yano T; Doi T; Ohtsu A; Boku N; Hashizume K; Nakanishi M; Ochiai A
Oncol Rep; 2006 Jan; 15(1):65-71. PubMed ID: 16328035
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of silver-enhanced in situ hybridization for evaluating HER2 gene status in invasive breast carcinoma: a comparative study.
Lee Y; Ryu Y; Jeong H; Chang H; Kim Y; Kim A
Arch Med Res; 2012 Feb; 43(2):139-44. PubMed ID: 22475781
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of automated silver-enhanced in situ hybridization (SISH) for detection of HER2 gene amplification in breast carcinoma excision and core biopsy specimens.
Shousha S; Peston D; Amo-Takyi B; Morgan M; Jasani B
Histopathology; 2009 Jan; 54(2):248-53. PubMed ID: 19207950
[TBL] [Abstract][Full Text] [Related]
17. HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH).
Boers JE; Meeuwissen H; Methorst N
Histopathology; 2011 Feb; 58(3):383-94. PubMed ID: 21323962
[TBL] [Abstract][Full Text] [Related]
18. False positivity in HER2 testing of breast cancer: novel paths for approaching an old dilemma.
Nunes CB; Rocha RM; Buzelin MA; Balabram D; de Souza Foureaux F; Porto SS; Gobbi H
J Clin Pathol; 2013 Nov; 66(11):946-50. PubMed ID: 23867547
[TBL] [Abstract][Full Text] [Related]
19. Relationship between HER2 status and proliferation rate in breast cancer assessed by immunohistochemistry, fluorescence in situ hybridisation and standardised AgNOR analysis.
Bánkfalvi A; Giuffrè G; Ofner D; Diallo R; Poremba C; Buchwalow IB; Barresi V; Böcker W; Tuccari G
Int J Oncol; 2003 Nov; 23(5):1285-92. PubMed ID: 14532967
[TBL] [Abstract][Full Text] [Related]
20. Delineation of HER2 gene status in breast carcinoma by silver in situ hybridization is reproducible among laboratories and pathologists.
Carbone A; Botti G; Gloghini A; Simone G; Truini M; Curcio MP; Gasparini P; Mangia A; Perin T; Salvi S; Testi A; Verderio P
J Mol Diagn; 2008 Nov; 10(6):527-36. PubMed ID: 18832456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
